Bristol-Myers Squibb Company

Company Overview

Business Model: Bristol-Myers Squibb Company is a global biopharmaceutical company focused on the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines. The Company's principal strategy is to combine the resources, scale, and capability of a large pharmaceutical company with the speed, agility, and focus on innovation typically found in the biotech industry. It concentrates on transformational medicines for serious diseases in oncology, hematology, immunology, cardiovascular, neuroscience, and other areas, aiming to create long-term value. Revenue is primarily generated through the sale of innovative pharmaceutical products worldwide.

Market Position: Bristol-Myers Squibb Company operates in broad-based and highly competitive markets, competing with other global research-based drug companies, smaller research firms, and generic drug manufacturers. Key competitive factors include product efficacy, safety, ease of use, price, cost-effectiveness, marketing effectiveness, and R&D of new products. The Company emphasizes its first-in-class and/or best-in-class marketed products and aims to maintain leadership through continuous innovation and strategic capital allocation. The Company faces increasing market penetration from lower-priced generic products following loss of market exclusivity.

Recent Strategic Developments: In 2025, Bristol-Myers Squibb Company achieved multiple regulatory approvals across its portfolio, including for Breyanzi in relapsed or refractory follicular lymphoma and mantle cell lymphoma in the EU, Camzyos for symptomatic obstructive hypertrophic cardiomyopathy in Japan, and Opdivo + Yervoy for first-line unresectable or advanced hepatocellular carcinoma in the U.S. and EU. The Company also received label updates reducing patient monitoring requirements for Camzyos, Breyanzi, and Abecma. Strategic business development activities included the acquisition of Orbital Therapeutics, a global strategic collaboration with BioNTech for pumitamig (BNT327/BMS986545), and a global exclusive licensing agreement with Philochem for OncoACP3. The Company also expanded its manufacturing capabilities by opening a new radiopharmaceutical facility in Indianapolis, Indiana, and completing a cell therapy manufacturing facility in Leiden, Netherlands.

Geographic Footprint: Bristol-Myers Squibb Company's products are sold worldwide. In 2025, 69% of total revenues were generated in the United States, and 29% from International markets. The Company has significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland. No single country outside the U.S. contributed more than 10% of total revenues in 2025.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 71.1%
• Operating Margin: 19.4%
• Net Margin: 14.6%

Investment in Growth:

• R&D Expenditure: $9,951 million (20.6% of revenue)
• Capital Expenditures: $1,311 million
• Strategic Investments:
  • Orbital Therapeutics acquisition: $1.7 billion total consideration ($1.4 billion expensed as Acquired IPRD)
  • BioNTech upfront fee for pumitamig collaboration: $1.5 billion (expensed as Acquired IPRD)
  • Philochem upfront fee for OncoACP3 license: $350 million (expensed as Acquired IPRD)
  • SystImmune upfront fee and milestone: $250 million (expensed as Acquired IPRD)
  • BioArctic upfront fee for PyroGlutamate-amyloid-beta antibody program: $100 million (expensed as Acquired IPRD)

Business Segment Analysis

Bristol-Myers Squibb Company operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines. The Chief Executive Officer, as the chief operating decision maker, uses consolidated net income or loss when managing and allocating resources at the corporate level, rather than on a product or franchise basis.

Product Portfolio Performance

Growth Portfolio

• Revenue: $26,409 million (+17.0% YoY)
• Opdivo: $10,049 million (+8.0% YoY)
  • U.S. Revenue: $5,904 million (+10.0% YoY)
  • Non-U.S. Revenue: $4,145 million (+5.0% YoY)
  • Key Growth Drivers: Higher demand in both U.S. and International markets, additional indication launches internationally.
• Opdivo Qvantig: $238 million (N/A, launched in U.S. in January 2025, EU approved May 2025)
  • U.S. Revenue: $205 million
  • Non-U.S. Revenue: $33 million
• Orencia: $3,705 million (+1.0% YoY)
  • U.S. Revenue: $2,736 million (-1.0% YoY)
  • Non-U.S. Revenue: $969 million (+6.0% YoY)
  • Key Growth Drivers: Higher international demand, partially offset by lower U.S. net selling prices.
• Yervoy: $2,900 million (+15.0% YoY)
  • U.S. Revenue: $1,825 million (+14.0% YoY)
  • Non-U.S. Revenue: $1,075 million (+15.0% YoY)
  • Key Growth Drivers: Higher demand and average net selling prices.
• Reblozyl: $2,327 million (+31.0% YoY)
  • U.S. Revenue: $1,888 million (+31.0% YoY)
  • Non-U.S. Revenue: $438 million (+33.0% YoY)
  • Key Growth Drivers: Higher demand in both U.S. and International markets, particularly in first-line RS-positive and RS-negative settings in the U.S.
• Breyanzi: $1,358 million (+82.0% YoY)
  • U.S. Revenue: $994 million (+68.0% YoY)
  • Non-U.S. Revenue: $364 million (+132.0% YoY)
  • Key Growth Drivers: Higher demand for core indications and additional indication launches in both U.S. and International markets.
• Opdualag: $1,185 million (+28.0% YoY)
  • U.S. Revenue: $1,045 million (+20.0% YoY)
  • Key Growth Drivers: Higher demand.
• Camzyos: $1,068 million (+77.0% YoY)
  • U.S. Revenue: $863 million (+59.0% YoY)
  • Non-U.S. Revenue: $204 million (>200% YoY)
  • Key Growth Drivers: Higher demand, driven by launches in new international markets.
• Zeposia: $577 million (+2.0% YoY)
  • U.S. Revenue: $392 million (-3.0% YoY)
  • Non-U.S. Revenue: $186 million (+14.0% YoY)
  • Key Growth Drivers: Higher international demand, offset by lower U.S. demand.
• Abecma: $427 million (+5.0% YoY)
  • U.S. Revenue: $208 million (-14.0% YoY)
  • Non-U.S. Revenue: $219 million (+34.0% YoY)
  • Key Growth Drivers: International growth due to favorable GTN adjustment and foreign exchange, offset by increased competition in BCMA targeted therapies in the U.S.
• Sotyktu: $291 million (N/A, launched in 2024)
  • U.S. Revenue: $182 million (-5.0% YoY)
  • Non-U.S. Revenue: $110 million (+99.0% YoY)
  • Key Growth Drivers: Higher international demand, offset by lower U.S. net selling prices.
• Krazati: $205 million (+62.0% YoY)
  • U.S. Revenue: $192 million (+63.0% YoY)
  • Key Growth Drivers: Higher demand.
• Cobenfy: $155 million (>200% YoY, launched in U.S. in October 2024)
  • U.S. Revenue: $155 million
• Other Growth Products: $1,924 million (+17.0% YoY)

Legacy Portfolio

• Revenue: $21,785 million (-15.3% YoY)
• Eliquis: $14,443 million (+8.3% YoY)
  • U.S. Revenue: $10,239 million (+6.0% YoY)
  • Non-U.S. Revenue: $4,205 million (+14.0% YoY)
  • Key Growth Drivers: Higher demand in both U.S. and International markets. Faces generic competition in certain EU countries.
• Revlimid: $2,951 million (-49.0% YoY)
  • U.S. Revenue: $2,535 million (-49.0% YoY)
  • Non-U.S. Revenue: $416 million (-46.0% YoY)
  • Key Growth Drivers: Significant decline due to generic erosion and lower average net selling prices, impacted by Medicare Part D redesign.
• Pomalyst/Imnovid: $2,733 million (-23.0% YoY)
  • U.S. Revenue: $2,341 million (-13.0% YoY)
  • Non-U.S. Revenue: $391 million (-54.0% YoY)
  • Key Growth Drivers: Decline due to generic erosion internationally and lower average net selling prices in the U.S. (Medicare Part D redesign). Generic entry expected in U.S. in March 2026.
• Sprycel: $493 million (-62.0% YoY)
  • U.S. Revenue: $299 million (-70.0% YoY)
  • Non-U.S. Revenue: $194 million (-36.0% YoY)
  • Key Growth Drivers: Significant decline due to generic erosion in U.S., EU, and Japan.
• Abraxane: $368 million (-58.0% YoY)
  • U.S. Revenue: $116 million (-78.0% YoY)
  • Key Growth Drivers: Significant decline due to generic erosion.
• Other Legacy Products: $798 million (-14.0% YoY)

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $0 million in 2025.
• Dividend Payments: $5,045 million in 2025.
• Future Capital Return Commitments: Remaining share repurchase capacity under the Board-authorized program was $5.0 billion as of December 31, 2025.

Balance Sheet Position:

• Cash and Equivalents: $10,209 million
• Total Debt: $45,111 million (Short-term debt obligations: $2,261 million; Long-term debt: $42,850 million)
• Net Cash Position: ($34,902) million (Net Debt Position: $34,902 million)
• Credit Rating: Moody’s: A2 (stable outlook); Standard & Poor’s: A (stable outlook).
• Debt Maturity Profile:
  • 2026: $2.0 billion
  • 2027: $2.0 billion
  • 2028: $544 million
  • 2029: $2.2 billion
  • 2030: $2.1 billion
  • Key maturities include 2.973% Euro Notes due 2030, 3.363% Euro Notes due 2033, 3.857% Euro Notes due 2038, 4.289% Euro Notes due 2045, and 4.581% Euro Notes due 2055.

Cash Flow Generation:

• Operating Cash Flow: $14,156 million
• Free Cash Flow: Not explicitly stated.

Operational Excellence

Production & Service Model: Bristol-Myers Squibb Company operates a manufacturing network, both internal and external, to enhance efficiency and maintain flexibility. Manufacturing processes are complex, highly regulated, and product-specific. The Company manages a flexible network to minimize product transfers and inefficient capacity use. It continues to invest in existing sites and expand manufacturing capabilities, particularly for biologics and cell therapy products, which involve technically sophisticated processes and specialized raw materials.

Supply Chain Architecture: The Company purchases raw materials, components, and supplies in the open market. For some products, it relies on single or sole sources. Mitigation strategies include inventory management and alternative sourcing. Third-party manufacturers are increasingly utilized for drug product and finished goods, especially for mature brands.

Key Suppliers & Partners:

• Manufacturing Partners: Third-party manufacturers are used for active product ingredients or drug substances for products like Eliquis, Opdivo, Pomalyst/Imnovid, Yervoy, Sprycel, Abraxane, Zeposia, Camzyos, Sotyktu, Krazati, and Cobenfy.
• Cell Therapy Manufacturing: Facilities in Bothell, Washington; Summit, New Jersey; Devens, Massachusetts; and Leiden, Netherlands (completed in 2025).
• Radiopharmaceutical Manufacturing: New facility opened in Indianapolis, Indiana in 2025.

Facility Network:

• Manufacturing: 8 significant facilities (4 in U.S., 4 International)
• Research & Development: 8 significant facilities (7 in U.S., 1 International). New R&D facilities opened in Cambridge, Massachusetts (2023) and Hyderabad, India (2024). A new R&D facility in San Diego, California is planned for 2026.
• Distribution: Supported by internal and third-party logistics.

Operational Metrics: Not explicitly disclosed in a consolidated format.

Market Access & Customer Relationships

Go-to-Market Strategy: Bristol-Myers Squibb Company promotes its products directly to healthcare professionals and organizations (doctors, pharmacists, hospitals, PBMs, MCOs). It also provides information to U.S. consumers through direct-to-consumer advertising. The Company focuses on gaining formulary access and reimbursement by demonstrating clinical profiles and cost advantages.

Distribution Channels:

• Direct Sales: Field sales and medical organizations engage directly with healthcare professionals. Direct-to-patient offerings were recently announced for several products in the U.S.
• Channel Partners: Products are sold principally to wholesalers, distributors, and specialty pharmacies.
• Digital Platforms: Online sales channels and e-commerce initiatives are utilized.
• Restricted Distribution Programs: Revlimid and Pomalyst are distributed in the U.S. through contracted pharmacies under Lenalidomide REMS and Pomalyst REMS programs. Camzyos is available only through the Camzyos REMS Program.

Customer Portfolio:

• Customer Concentration: The three largest pharmaceutical wholesalers in the U.S. accounted for approximately 87% of total gross sales of U.S. products in 2025. Receivables from these three customers represented 75% of total trade receivables at December 31, 2025.

Geographic Revenue Distribution:

• United States: 69% of total revenue
• International: 29% of total revenue
• Other (royalties and alliance-related revenues for products not sold by regional commercial organizations): 2% of total revenue

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical industry is highly competitive, with rapid advancements, particularly in immuno-oncology (IO) therapies. The market is characterized by intense competition based on product efficacy, safety, price, and innovation. Generic and biosimilar manufacturers pose significant competitive challenges, leading to substantial and rapid declines in sales for innovative products upon loss of market exclusivity.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Other global research-based drug companies, smaller research companies with limited therapeutic focus, and generic drug manufacturers. Specific competitors are not named in the filing, but the competitive landscape for IO products (e.g., Opdivo) is highlighted as highly competitive.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions, particularly in IO and other therapeutic areas. Generic and biosimilar challenges are increasing, with manufacturers actively seeking to challenge patents.

Competitive Response Strategy: The Company's strategy focuses on discovering and developing innovative, cost-effective products that address unmet medical needs, efficient manufacturing, and effective marketing. It aims to expand the value of existing products through new indications and formulations and to accelerate pipeline delivery through internal R&D and strategic business development activities.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect revenues and profit margins. The Inflation Reduction Act of 2022 (IRA) is expected to reduce prices and reimbursements for certain products (e.g., Eliquis, Pomalyst, Orencia), potentially accelerating revenue erosion.
• Technology Disruption: High rate of failure in R&D (93% for small molecules, 91% for biologics from Phase I). Product candidates may fail to reach market or gain approval.
• Customer Concentration: Dependence on a few key products (Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl, Yervoy) for a majority of revenues, cash flows, and earnings. A reduction in revenue from any of these could have a material adverse impact.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Difficulties, delays, and disruptions in manufacturing, distribution, and sale of products due to regulatory non-compliance, supply problems, geopolitical factors, supplier failures (including sole/single source), construction delays, and issues with complex manufacturing processes (e.g., CAR-T cell therapies, radiopharmaceuticals).
• Capacity Constraints: Manufacturing processes for novel cell-based therapies and radiopharmaceutical therapeutics are evolving and may be more complicated or expensive. Challenges with sourcing raw materials and developing consistent, reliable manufacturing processes and distribution networks could impact future revenue and gross profit.

Financial & Regulatory Risks

• Market & Financial Risks: Significant indebtedness from recent acquisitions could reduce financial flexibility. Adverse changes in U.S. and global economic and political conditions, including a strengthening U.S. dollar, global inflation, and customer credit risks in international markets, could negatively affect operations and profitability.
• Regulatory & Compliance Risks: Extensive global regulations govern testing, approval, production, labeling, distribution, marketing, and promotion. Non-compliance can lead to legal or regulatory action, fines, and product withdrawals. New laws (e.g., IRA, OBBBA) and state-level actions on drug pricing and reimbursement could further constrain pricing and market access. Cybersecurity and data privacy regulations are evolving, with non-compliance risking significant penalties and reputational harm.

Geopolitical & External Risks

• Geographic Dependencies: Significant international operations (29% of revenues) expose the Company to risks such as currency fluctuations, nationalization, price/exchange controls, counterfeit products, and other restrictive governmental actions.
• Trade Relations: New tariffs could impact business, though pharmaceuticals were largely exempt in 2025. The U.S. Government Agreement provides certain U.S. tariff relief until January 2029 and exemption from future U.S. pricing mandates, but the Company remains subject to international mandates.
• Sanctions & Export Controls: Not explicitly detailed as a specific risk category, but general geopolitical risks are mentioned.

Innovation & Technology Leadership

Research & Development Focus: Bristol-Myers Squibb Company's R&D strategy focuses on science, execution, and value, investing in promising science to translate into new medicines. Key disease areas include oncology, hematology, immunology, cardiovascular, and neuroscience. The Company aims to increase the probability of success in clinical trials and is integrating artificial intelligence into its R&D process.

Core Technology Areas:

• Small Molecule Drugs: Includes protein degraders.
• Biologics: Drugs produced from biological processes.
• ADCs (Antibody-Drug Conjugates):
• CAR-T Cell Therapies: CD19-directed and BCMA genetically modified autologous CAR-T cell therapies.
• Radiopharmaceutical Therapeutics: Actinium-based RPTs.

Innovation Pipeline: The Company has a broad pipeline with over 45 unique assets in development, built through internal R&D and a distributed R&D model with external partnerships. Key late-stage programs include:

• Hematology: BCL6 LDD, iberdomide, mezigdomide, arlo-cel, Reblozyl (additional indications).
• Oncology: Anti-CCR8, Krazati (additional indications), RYZ101, Opdivo (additional indications), Opdivo Qvantig + Yervoy (additional indications).
• Immunology: BMS-986454, zola-cel (CD19-targeted NEX-T), Sotyktu (additional indications), admilparant.
• Cardiovascular: MYK-224, milvexian.
• Neuroscience: BMS-986495, Anti-MTBR Tau, Cobenfy (additional indications).

Intellectual Property Portfolio: The Company owns or licenses numerous patents in the U.S. and foreign countries covering its products, formulations, uses, delivery mechanisms, and manufacturing processes. It also holds many brand names and trademarks. Market exclusivity is determined by patent rights and regulatory exclusivity periods (e.g., 5 years for chemical products, 12 years for biologics in the U.S.; "8+2+1" regime in EU). The Company actively defends its intellectual property rights against infringement and generic challenges.

Technology Partnerships:

• BioNTech: Global strategic collaboration for co-development and co-commercialization of pumitamig (bispecific antibody).
• Philochem: Global exclusive license for OncoACP3 (radiopharmaceutical therapeutic and diagnostic agent).
• BioArctic: Global exclusive license for PyroGlutamate-amyloid-beta antibody program (Alzheimer's Disease).
• SystImmune: Global strategic collaboration for co-development and co-commercialization of izalontamab brengitecan (bispecific topoisomerase inhibitor-based antibody drug conjugate).
• Merck: Licensing agreement for Reblozyl (BMS pays royalties to Merck) and Winrevair* (BMS receives royalties from Merck).
• Pfizer: Joint development and commercialization of Eliquis.
• Janssen: Joint development of milvexian (Factor XIa inhibitor).
• Ono Pharmaceutical Co., Ltd.: Joint development and commercialization of Opdivo, Yervoy, and Orencia in Japan, South Korea, and Taiwan.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's People Strategy is designed to empower employees and foster an inclusive workplace that attracts, develops, and retains top talent. It invests in enterprise-wide programs for career growth, internal mobility, and leadership development.

Board Composition: The Audit Committee, consisting solely of independent directors, oversees the Company’s overall enterprise risk assessment and risk management policies, including cybersecurity. The Audit Committee receives periodic updates from the CISO, CPO, internal audit function, and other management members.

Human Capital Strategy

Workforce Composition: As of December 31, 2025, Bristol-Myers Squibb Company had approximately 32,500 employees in 43 countries. Approximately 54% of employees are located in the U.S. (excluding Puerto Rico), and 46% are located outside the U.S. The workforce is supplemented by contingent and temporary workers.

Talent Management:

• Acquisition & Retention: The Company prioritizes investment in programs and policies to accelerate development and collaboration, aiming to create a competitive advantage in recruiting, developing, and retaining talent.
• Employee Value Proposition: Offers market-competitive base salaries, annual incentives tied to company and individual performance, and long-term equity incentives focused on value creation. Comprehensive and inclusive benefits and well-being resources are provided.

Diversity & Development: The Company is committed to empowering employees with skills and capabilities for growth and patient impact. It invests in next-generation platforms for career ownership, internal mobility, and just-in-time learning. There is a focus on upskilling the workforce in AI and providing leadership development resources.

Environmental & Social Impact

Environmental Commitments: The Company's operations are subject to extensive U.S. and foreign environmental protection and human health and safety laws. It incurs operating and capital costs for compliance and invests in projects to reduce energy and water use. The environment, occupational health, safety, and sustainability group monitors operations and oversees compliance standards.

Supply Chain Sustainability: The Company's environmental, social, and governance (ESG) policies extend to its supply chain, with increasing focus from regulators, investors, and stakeholders on environmental sustainability and social impact.

Social Impact Initiatives: The Company mobilizes capabilities and resources to positively impact communities globally. Its culture is defined by an unyielding focus on patients, guided by core values of Integrity, Passion, Inclusion, Innovation, Accountability, and Urgency.

Business Cyclicality & Seasonality

Demand Patterns: The Company's business is typically not seasonal. However, the first quarter usually sees an unwinding of sales channel inventory build-up from the fourth quarter of the prior year.

Planning & Forecasting: Demand forecasting and inventory management are influenced by factors such as generic erosion, seasonality, wholesaler purchases, new product launches, and third-party data.

Regulatory Environment & Compliance

Regulatory Framework: The pharmaceutical industry is subject to extensive global regulations governing testing, approval, production, labeling, distribution, post-market surveillance, advertising, and promotion. The FDA in the U.S. and EMA in the EU are key regulatory bodies. Compliance with cGMP is mandated.

• Industry-Specific Regulations: The Inflation Reduction Act of 2022 (IRA) significantly impacts drug pricing for Medicare Part B and D, requiring price "negotiations" and rebates for price increases exceeding inflation. The One, Big, Beautiful Bill Act (OBBBA) aims for efficiencies in U.S. federal government healthcare spending, primarily within Medicaid, and modifies international tax frameworks. State laws are also emerging to regulate drug pricing and reimbursement.
• International Compliance: Regulatory requirements vary by country, and approval in one country does not assure approval in another. Many international markets have government-mandated cost-containment programs, including direct price controls, international price comparisons, and rebate schemes.

Trade & Export Controls: The U.S. and other countries have imposed, and may continue to impose, new tariffs. While pharmaceuticals were largely exempt in 2025, this may change. The U.S. Government Agreement provides Bristol-Myers Squibb Company with certain U.S. tariff relief until January 2029 and exemption from future U.S. pricing mandates, but it remains subject to international mandates.

Legal Proceedings: Bristol-Myers Squibb Company is involved in various lawsuits, claims, government investigations, and legal proceedings, including patent litigation (e.g., Eliquis, Pomalyst, Zeposia), pricing, sales, and promotional practices litigation (e.g., Plavix*), securities litigation (e.g., Celgene Securities Litigations, Contingent Value Rights Litigations), and challenges to government regulations (e.g., IRA Litigation, 340B Litigation). Environmental proceedings related to contamination at current or former sites are also ongoing.

Tax Strategy & Considerations

Tax Profile: The effective tax rate for 2025 was 24.4%, primarily impacted by a $1.4 billion non-tax deductible charge for the Orbital Therapeutics acquisition and jurisdictional earnings mix. The OBBBA, enacted in July 2025, allows immediate deduction of qualifying domestic R&D expenses for tax years beginning after December 31, 2024, and accelerates deductions for deferred R&D expenses from 2022-2024.

• Effective Tax Rate: 24.4% (2025)
• Geographic Tax Planning: The Company is subject to income taxes in the U.S. and various other countries globally. It is not indefinitely reinvested with respect to undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign and state income and withholding tax.
• Tax Reform Impact: The IRA and OBBBA have significant implications for the Company's tax provision and results of operations, including changes to the international tax framework and R&D expense deductibility.

Insurance & Risk Transfer

Risk Management Framework: The Company uses certain derivative financial instruments to hedge underlying economic exposures to currency exchange rates and interest rates. These include foreign currency forward and purchased local currency put option contracts, and cross-currency swap contracts. Derivatives are not used for trading purposes. The Company monitors counterparty credit risk by limiting amounts outstanding and engaging with high-credit-quality institutions.